Pipeline Exploration

About Amarin

Amarin is a commercial-stage biopharmaceutical company focused on redefining cardiovascular disease (CVD) management. Its success is built upon the landmark REDUCE-IT outcomes trial for its flagship product, icosapent ethyl (VASCEPA/VAZKEPA), which demonstrated significant cardiovascular risk reduction in high-risk patients on statins. The company's strategy centers on maximizing the global commercial footprint of this proven therapy while exploring additional pipeline opportunities to expand its impact on cardiometabolic health.

Therapeutic Areas